TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29747269

Group type: EXPERIMENTAL
Intervention: Low-dose CEE + progesterone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Standard-dose CEE + progesterone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Standard-dose CEE + dydrogesterone
Number of subjects: 123

Group type: COMPARATOR
Intervention: All groups (Low-dose CEE + progesterone, Standard-dose CEE + progesterone, Standard-dose CEE + dydrogesterone
Number of subjects: 123
Study: 27509607

Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 85
Study: 25515698

Group type: EXPERIMENTAL
Intervention: Fixed dose ASAQ (600 mg AS + 1,620 mg AQ)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-fixed ASAQ (600 mg AS + 1,836 mg AQ)
Number of subjects: 54
Study: 22354104

Group type: EXPERIMENTAL
Intervention: Double-injection US-guided AXB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triple-injection US-guided AXB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Quadruple-injection US-guided AXB
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups (double, triple, quadruple injections)
Number of subjects: 120
Study: 20034440

Group type: EXPERIMENTAL
Intervention: Needle-free acupuncture
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional needle injection acupuncture
Number of subjects: 101
Study: 17664116

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 15644019

Group type: EXPERIMENTAL
Intervention: Bispectral Index (Aspect Medical)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: AAI auditory evoked potential (Danmeter)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Entropy (Datex-Ohmeda)
Number of subjects: 21
Study: 12370684

Group type: EXPERIMENTAL
Intervention: Thoracic morphine epidural analgesia (TEA) - continuous infusion of 15 mg of morphine in 250 mL of normal saline at 5 mL/h.
Number of subjects: 563

Group type: COMPARATOR
Intervention: Intravenous analgesia (IVA) - continuous infusion of 30 mg of morphine and 180 mg ketorolac in 250 mL of normal saline at 5 mL/h.
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Comparison of TEA and IVA
Number of subjects: 563
Study: 10757583

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 microg kg(‐1) + Propofol 2.5 mg kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 microg kg(‐1) + Propofol 2.5 mg kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil 30 microg kg(‐1) + Propofol 2.5 mg kg(‐1)
Number of subjects: 60
Study: 9018491

Group type: COMPARATOR
Intervention: Diet only (DO)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Diet combined with aerobic exercise (DA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Diet combined with resistance exercise (DR)
Number of subjects: 33
Study: 1444652

Group type: EXPERIMENTAL
Intervention: Plasma-TFE VA
Number of subjects: 67

Group type: COMPARATOR
Intervention: e-PTFE
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Plasma-TFE AVA
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Plasma-TFE (VA and AVA)
Number of subjects: 67
Study: 3866256

Group type: EXPERIMENTAL
Intervention: Ofloxacin 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg
Number of subjects: 13
Study: 31506369

Group type: EXPERIMENTAL
Intervention: Manual blood pressure measurement
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Automated blood pressure measurement
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Chair position blood pressure measurement
Number of subjects: 294

Group type: COMPARATOR
Intervention: Table position blood pressure measurement
Number of subjects: 294
Study: 30366647

Group type: EXPERIMENTAL
Intervention: Laparoscopic scoring assessment with PIV score <8
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Laparoscopic scoring assessment with PIV score ≥8
Number of subjects: 226

Group type: COMPARATOR
Intervention: Laparoscopic scoring assessment
Number of subjects: 226
Study: 27776149

Group type: EXPERIMENTAL
Intervention: 6 mg caffeine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24964509

Group type: EXPERIMENTAL
Intervention: Plasma vitamin A levels in MS patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Plasma vitamin C levels in MS patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Plasma vitamin E levels in MS patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (healthy individuals without MS)
Number of subjects: 68
Study: 23615384

Group type: EXPERIMENTAL
Intervention: Specific trunk exercises group (SEG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Stationary cycling group (CEG)
Number of subjects: 64
Study: 20092410

Group type: EXPERIMENTAL
Intervention: Formal training with instruction from an attending robotic surgeon
Number of subjects: 43

Group type: COMPARATOR
Intervention: Informal practice session with the robot
Number of subjects: 43
Study: 18187374

Group type: EXPERIMENTAL
Intervention: 750 mg oral ursodeoxycholic acid (UDCA) daily for 6 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 16133790

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg three times daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 14557560

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the VIM thalamic nucleus
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control subjects (age- and sex-matched)
Number of subjects: 6
Study: 11234738

Group type: EXPERIMENTAL
Intervention: Guidelines and access to a fast‐track investigation service for urological conditions
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional tests (not accounting for clustering)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cluster level analysis with no account for cluster size
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Weighted cluster level analysis
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Advanced statistical methods (random effects models and generalised estimating equations)
Number of subjects: 66
Study: 8803645

Group type: EXPERIMENTAL
Intervention: Intravenous flumazenil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 1472339

Group type: EXPERIMENTAL
Intervention: AIDS education intervention (lectures, role‐plays, posters, pamphlets)
Number of subjects: 641
Study: 31585096

Group type: EXPERIMENTAL
Intervention: Transabdominal cerclage
Number of subjects: 111

Group type: COMPARATOR
Intervention: High vaginal cerclage
Number of subjects: 111
Study: 30807545

Group type: EXPERIMENTAL
Intervention: Neurobehavioral function assessed using the Vineland Adaptive Behavior Scales, Second Edition at baseline, 3 months, and 12 months postcardiac arrest.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scales, Second Edition scores at 3 months and 12 months.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison with Therapeutic Hypothermia after Pediatric Cardiac Arrest group without precardiac arrest neurobehavioral impairment.
Number of subjects: 84
Study: 27870804

Group type: EXPERIMENTAL
Intervention: Low-load motor control (LMC) exercises
Number of subjects: 65

Group type: COMPARATOR
Intervention: High-load lifting (HLL) exercise (deadlift)
Number of subjects: 65
Study: 25909208

Group type: EXPERIMENTAL
Intervention: Generic enoxaparin (HeptronTM) for DVT therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Branded enoxaparin (Sanofi‐Aventis) for DVT therapy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Generic enoxaparin (HeptronTM) for DVT prophylaxis
Number of subjects: 114

Group type: COMPARATOR
Intervention: Branded enoxaparin (Sanofi‐Aventis) for DVT prophylaxis
Number of subjects: 114
Study: 22914876

Group type: EXPERIMENTAL
Intervention: Prior brace treatment for over 1 year (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No prior treatment (Group B)
Number of subjects: 70
Study: 21420599

Group type: EXPERIMENTAL
Intervention: 0.25 mg/mL diclofenac sodium
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.25 mg/mL combined diclofenac sodium and nuclear rotation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Balanced salt solution (Group 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lidocaine (Group 2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Group 3)
Number of subjects: 72
Study: 19864903

Group type: EXPERIMENTAL
Intervention: Experimental solution (1,900 mg/kg Sn as SnCl(2), 500 mg/kg F as NaF, 500 mg/kg F as amine fluoride, pH 4.5)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NaF solution (positive control, 1,000 mg/kg F, pH 4.5)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 20
Study: 17519820

Group type: EXPERIMENTAL
Intervention: Oral multi-drug chemotherapy (CCNU, cyclophosphamide, etoposide)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Classical intravenous chemotherapy (CAV: cyclophosphamide, doxorubicin, vincristine)
Number of subjects: 138
Study: 15369510

Group type: EXPERIMENTAL
Intervention: G group (genotypic group)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: GP group (geno-pharmacological group)
Number of subjects: 134
Study: 11443179

Group type: EXPERIMENTAL
Intervention: 1 mg micronized estradiol‐17beta orally, twice daily for 14 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9488131

Group type: EXPERIMENTAL
Intervention: Mixed technique using one electron and three photon beams with a common isocentre for all beams aided by a multileaf collimator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventionally used technique using two opposed tangential photon beams
Number of subjects: 30
Study: 7986469

Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fosinopril and exercise combined
Number of subjects: 0
Study: 2564110

Group type: EXPERIMENTAL
Intervention: Rifampicin (10 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Phenobarbitone (3 mg/kg)
Number of subjects: 22
Study: 31154479

Group type: EXPERIMENTAL
Intervention: Intensified multiple risk factor intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional multiple risk factor intervention
Number of subjects: 160
Study: 28704685

Group type: EXPERIMENTAL
Intervention: Higher Activity foot
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lower Activity foot
Number of subjects: 21
Study: 26205747

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (NSPT) in the form of scaling and root planing (SRP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no periodontal therapy)
Number of subjects: 70
Study: 23585306

Group type: EXPERIMENTAL
Intervention: Test formulation of ibuprofen (400 mg ibuprofen/20 mL suspension)
Number of subjects: 20
Study: 21672969

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg i.v./6 weeks for 8 years
Number of subjects: 69
Study: 19682233

Group type: EXPERIMENTAL
Intervention: Pre-hospital high-dose tirofiban
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Control (no high-dose tirofiban/placebo)
Number of subjects: 1398
Study: 17237736

Group type: EXPERIMENTAL
Intervention: Young sex workers (16-19 years)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Older sex workers (20 years and older)
Number of subjects: 1000
Study: 14736293

Group type: EXPERIMENTAL
Intervention: Hill-climbing heuristic applied to the 6-coin problem with a concrete and visualizable solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hill-climbing heuristic applied to a version of the problem requiring insight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conceptual difficulty in potential insight solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Move selection principles on the 6-coin and 10-coin (triangle) problems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postsolution receding
Number of subjects: 0
Study: 11179136

Group type: EXPERIMENTAL
Intervention: Noninvasive Positive Pressure Ventilation (NPPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative pressure ventilation or abdominal displacement ventilators
Number of subjects: 0
Study: 9154546

Group type: EXPERIMENTAL
Intervention: Torovirus antigen detection in children with acute diarrhea (n=33)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Torovirus antigen detection in children with persistent diarrhea (n=41)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (children without diarrhea, n=17)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Presence of enteroaggregative E. coli in children with persistent diarrhea
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Presence of Cryptosporidium oocysts in children with diarrhea
Number of subjects: 91
Study: 8201374

Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 3504454

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (0.5 mg) placed intracervically
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pretreatment prior to labor induction)
Number of subjects: 0
Study: 31592387

Group type: EXPERIMENTAL
Intervention: dHACA (AmnioBand)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TESS (Apligraf)
Number of subjects: 60
Study: 29281604

Group type: EXPERIMENTAL
Intervention: Statins plus evolocumab
Number of subjects: 968

Group type: COMPARATOR
Intervention: Statins alone
Number of subjects: 968
Study: 25478758

Group type: EXPERIMENTAL
Intervention: TII SCB
Number of subjects: 64

Group type: COMPARATOR
Intervention: ICB
Number of subjects: 64
Study: 23480592

Group type: EXPERIMENTAL
Intervention: Discontinued glimepiride
Number of subjects: 56

Group type: COMPARATOR
Intervention: 50% reduced dose of metformin
Number of subjects: 56
Study: 20535638

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily (Group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rowatinex 100 mg capsules 3 times a day (Group 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac 100 mg once daily (Group 3)
Number of subjects: 90
Study: 19232658

Group type: EXPERIMENTAL
Intervention: Interventions for malaria management
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Interventions for leishmaniasis management
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Interventions for lymphatic filariasis management
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Interventions for schistosomiasis management
Number of subjects: 38
Study: 17253883

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0
Study: 15817726

Group type: EXPERIMENTAL
Intervention: Dipyridamole (12 microg.min(‐1).dl forearm(‐1))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Time-control study without dipyridamole
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simultaneous intrabrachial infusion of dipyridamole and adenosine (100 microg.min(‐1).dl(‐1) dipyridamole and 5 microg.min(‐1).dl(‐1) adenosine)
Number of subjects: 26
Study: 12213183

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Funding source
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quality scores
Number of subjects: 100
Study: 9863862

Group type: EXPERIMENTAL
Intervention: Once daily (qd) dosing of didanosine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Twice daily (bid) dosing of didanosine
Number of subjects: 19
Study: 8520180

Group type: EXPERIMENTAL
Intervention: Nafarelin (two 400-micrograms doses intranasally 16 hours apart, followed by 7 more doses on LD6)
Number of subjects: 26

Group type: COMPARATOR
Intervention: hCG (5000 IU intramuscularly on luteal day 0, followed by a single 2500 IU dose on LD6)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 26

Group type: COMPARATOR
Intervention: hCG
Number of subjects: 26
Study: 2090208

Group type: EXPERIMENTAL
Intervention: One single dose of 4 g piperacillin 30 minutes before surgery
Number of subjects: 93

Group type: COMPARATOR
Intervention: Three doses of 4 g piperacillin (30 minutes before surgery, and 6 & 12 hours after surgery)
Number of subjects: 93
Study: 556137

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daranide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31960695

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation plus hyperproteic oral nutritional supplement (PRS) enriched with beta-hydroxy-beta-methylbutyrate (HMB)
Number of subjects: 30
Study: 31897428

Group type: EXPERIMENTAL
Intervention: SYNT001 (FcRn-blocking monoclonal antibody)
Number of subjects: 0
Study: 28327503

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (140 mL; 800 mg nitrate/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BR)
Number of subjects: 32
Study: 26083948

Group type: EXPERIMENTAL
Intervention: Aspirin desensitization (AD) with increasing doses of aspirin (60, 125, 325, and 625 mg) followed by 625 mg twice daily for 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aspirin desensitization (AD)
Number of subjects: 34
Study: 23462833

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus Atorvastatin 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 30
Study: 21276586

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Simvastatin plus fenofibrate
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Simvastatin and fenofibrate (combined)
Number of subjects: 196
Study: 20183663

Group type: EXPERIMENTAL
Intervention: Cognitive Distortions and Maladaptive Beliefs
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Cognitive Avoidance
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Positive Outlook
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Solution‐Focused Thinking
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Maladaptive cognitions
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Negative cognitions
Number of subjects: 390
Study: 16395269

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose 100 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15312371

Group type: EXPERIMENTAL
Intervention: Postoperative TACE and thymosin alpha(1) (T(alpha1)) treatment (Group A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Postoperative TACE (Group B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hepatectomy only (Group C)
Number of subjects: 57
Study: 11774937

Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Dietary supplementation with ascorbic acid and/or beta-carotene
Number of subjects: 132
Study: 9260798

Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspirin (1, 300 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8395916

Group type: EXPERIMENTAL
Intervention: Dronabinol 5 mg twice daily before meals
Number of subjects: 12
Study: 3805547

Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (180 micrograms)
Number of subjects: 10
Study: 29016880

Group type: EXPERIMENTAL
Intervention: Intranasal hydrocodone ER
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal hydrocodone powder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HYD-OF (hydrocodone bitartrate ER capsules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact oral hydrocodone ER
Number of subjects: 0
Study: 27476641

Group type: EXPERIMENTAL
Intervention: Group discussion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 60
Study: 24535134

Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg once-daily
Number of subjects: 1331

Group type: COMPARATOR
Intervention: IFNβ-1a IM 30 μg once-weekly
Number of subjects: 1331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1331
Study: 24084625

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 3602
Study: 22204569

Group type: EXPERIMENTAL
Intervention: Positive and Negative Syndrome Scale (PANSS)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Montgomery‐Asberg Depression Rating Scale (MADRS)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Subjective Well‐being Under Neuroleptics Scale Short Form (SWN‐K)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Schizophrenia Objective Functioning Instrument (SOFI)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Quality of Life Scale (QLS)
Number of subjects: 628
Study: 18248876

Group type: COMPARATOR
Intervention: Standard schedule (4 weekly and 5 monthly instillations of 50mg epirubicin/50 ml NaCl)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Early instillation (same schedule as group 1 with an additional instillation <48 h after TURBT)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Maintenance schedule (same schedule as group 1 with additional instillations at 9 and 12 months)
Number of subjects: 731